A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Efficacy of OBI-858 in Patients with Moderate-to-Severe Glabellar Lines - Top-Institutions - MDSpire

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Efficacy of OBI-858 in Patients with Moderate-to-Severe Glabellar Lines

  • By

  • Yu-Hsiu Yen

  • Tzu-Wen Tsau

  • Chih-Hung Lee

  • Hsin-Han Chen

  • Chih-Hung Lin

  • Tim-Mo Chen

  • Chi-Ming Pu

  • November 1, 2025

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Dermatology
    • Neurology
    • Plastic Surgery
  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Dermatology
    • Neurology
    • Plastic Surgery
  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Neurology
    • Plastic Surgery
  • #4

    Massachusetts General Hospital (MGH)
    Massachusetts General Hospital (MGH)

    Boston, MA

    Key Differentiators

    • Dermatology
    • Neurology
    • Plastic Surgery
  • #5

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Neurology
    • Plastic Surgery

Original Source(s)

Related Content